GlassScriptPhysician profile
Kelli Mcgee Plunk
NPI 1265942288
$10,446.87
in general payments reported to CMS, 2019-2025
37 companies · $3,136 in 2025
The $3,136 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,248 · 2022: $1,333 · 2023: $2,071 · 2024: $2,658 · 2025: $3,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825 · Education: $40.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,824.66 |
| Education | $40.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,886.46 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,786.60 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,212.22 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Harmony Biosciences LLC | $597.37 | 2021-2025 | Wakix |
| Merck Sharp & Dohme LLC | $416.90 | 2022-2025 | Zerbaxa, Recarbrio, Winrevair |
| Genzyme Corporation | $409.98 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $387.72 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $366.95 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $349.16 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $348.54 | 2021-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $320.71 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.67 | 2021-2025 | Glassia |
| Mylan Specialty L.P. | $256.65 | 2021-2024 | Yupelri |
| Insmed, INC. | $252.81 | 2021-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $200.25 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $196.28 | 2022-2025 | Prolastin-C Liquid |
| Electromed, INC. | $150.48 | 2024-2025 | Smartvest |
| Amgen INC. | $148.82 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $128.02 | 2021-2025 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $114.50 | 2021-2024 | |
| Pulmonx Corporation | $110.37 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Baxter Healthcare | $95.84 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| La Jolla Pharmaceutical Company | $74.07 | 2021-2025 | Giapreza |
| Viatris Specialty LLC | $60.85 | 2025 | Yupelri |
| Verona Pharma, INC. | $57.26 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $40.48 | 2025 | Uptravi, Opsynvi, Opsumit |
| Axsome Therapeutics, INC. | $33.10 | 2025 | Sunosi |
| 3b Medical, INC. | $31.86 | 2024-2025 | Luna |
| Shionogi INC | $24.20 | 2022 | |
| Fisher & Paykel Healthcare INC | $21.12 | 2025 | Fisher & Paykel Healthcare |
| Cardiva Medical, INC. | $21.05 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Ambu INC. | $18.88 | 2022 | |
| Philips North America LLC | $17.09 | 2024 | (Ak6) Vest Therapy |
| Resmed Corp | $16.06 | 2024 | |
| Liquidia Technologies, INC. | $14.62 | 2025 | Yutrepia |
| Janssen Pharmaceuticals, INC | $13.17 | 2021 | |
| Breas Medical, INC. | $3.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Plunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.